After having served the Turkish rare diseases community for many years from Ankara, we are happy to annouce that CarthaGenetics® is now also established in Istanbul with its new office in. Nidakule KozyatagiKozyatagi MahallesiDegirmen Sk. 18/19B, Kat 1034742 Kadikoy/IstanbulTurkey We look forward to receiving you there. ...
CarthaGenetics® will attend BioPharm America from 5th to 6th of September 2018 in Hynes Convention Center, Boston, MA.If you would like to arrange a meeting with us, do not hesitate to contact our CEO Philippe Carteron de Balmont at(phcarteron@carthagenetics.com) . ...
Nativa LLC is a full-cycle Russian pharmaceutical company founded in 2010, developing and producing world-class complex medicaments essential for human health. It focuses on oncology, pulmonology, multiple sclerosis and other fields. CarthaGenetics® is focusing on finding innovative early patients access to medicines for treating unmet needs and...
Turkish health sector has been changed completely with the Health Transformation Project lead by Ministry of Health. In this process of change, healthcare providers have become more competitive in healthcare market. As a result of project the health expenditures has beenincreased and policy makers implemented...
The book titled as “Pharmaceutical Market Access in Developed Markets” under Dr. Guvenc Kockaya (CarthaGenetics market Access Director) and Prof. Albert Wert heimer’s editorialship has been published for pre-order on Amazon. Market access is the process by which a pharmaceutical company gets its product available on...
Draft HTA report about HIPEC under Dr. Guvenc Kockaya`s authorship has been published by Ministry of Health of Turkey. The report will be online up to 9th November 2017 for getting comments from community. The final report will be published after review of comments.http://www.hta.gov.tr/hipec_taslak.aspxKeep track,...